Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Background Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and their imp...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2024-12-01
|
| coleção: | Journal of Dermatological Treatment |
| Assuntos: | |
| Acesso em linha: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2329240 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
